Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

762 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A case of high-risk AML in a patient with advanced systemic mastocytosis.
Fazio M, Vetro C, Markovic U, Duminuco A, Parisi M, Maugeri C, Mauro E, Parrinello NL, Stagno F, Villari L, Triolo AM, Stella S, Palumbo GA, Di Raimondo F, Romano A, Zanotti R. Fazio M, et al. Among authors: parisi m. Clin Case Rep. 2023 Jul 17;11(7):e7134. doi: 10.1002/ccr3.7134. eCollection 2023 Jul. Clin Case Rep. 2023. PMID: 37469366 Free PMC article.
The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents.
Romano A, Laura Parrinello N, Cerchione C, Letizia Consoli M, Parisi M, Calafiore V, Martino E, Conticello C, Di Raimondo F, Alberto Palumbo G. Romano A, et al. Among authors: parisi m. Blood Cancer J. 2017 Dec 15;7(12):649. doi: 10.1038/s41408-017-0019-6. Blood Cancer J. 2017. PMID: 29242558 Free PMC article. No abstract available.
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy.
Romano A, Parrinello NL, La Cava P, Tibullo D, Giallongo C, Camiolo G, Puglisi F, Parisi M, Pirosa MC, Martino E, Conticello C, Palumbo GA, Di Raimondo F. Romano A, et al. Among authors: parisi m. Expert Rev Mol Diagn. 2018 Jul;18(7):675-683. doi: 10.1080/14737159.2018.1470929. Epub 2018 May 3. Expert Rev Mol Diagn. 2018. PMID: 29707981
Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network.
Conticello C, Romano A, Del Fabro V, Martino EA, Calafiore V, Sapienza G, Leotta V, Parisi MS, Markovic U, Garibaldi B, Leotta S, Cotzia E, Innao V, Mannina D, Neri S, Musso M, Scalone R, Cangialosi C, Acquaviva F, Cardinale G, Merenda A, Maugeri C, Uccello G, Poidomani M, Longo G, Carlisi M, Tibullo D, Di Raimondo F. Conticello C, et al. Among authors: parisi ms. J Clin Med. 2019 Jun 19;8(6):877. doi: 10.3390/jcm8060877. J Clin Med. 2019. PMID: 31248142 Free PMC article.
Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey.
Markovic U, Romano A, Del Fabro V, Bellofiore C, Bulla A, Parisi MS, Leotta S, Gentile M, Cangialosi C, Vincelli I, Mineo G, Rossi M, Poidomani M, Uccello G, Maugeri C, Mannina D, Innao V, Di Raimondo F, Conticello C. Markovic U, et al. Among authors: parisi ms. Front Oncol. 2021 Mar 5;11:624405. doi: 10.3389/fonc.2021.624405. eCollection 2021. Front Oncol. 2021. PMID: 33763359 Free PMC article.
762 results